mRNA 5' Cap Characterization Service
In the rapidly evolving landscape of therapeutic nucleic acids, the 5' cap structure of messenger RNA (mRNA) stands as a critical quality attribute (CQA) that directly dictates the efficacy, stability, and safety of the final product. The 5' cap, typically consisting of an N7-methylguanosine (m7G) moiety joined to the first transcribed nucleotide via a 5'-5' triphosphate bridge, is essential for protecting mRNA from 5' exonuclease degradation, facilitating nuclear export, and recruiting the eukaryotic translation initiation factor 4E (eIF4E). At CD BioGlyco, we recognize that for mRNA-based vaccines and therapeutics, achieving high capping efficiency and the correct cap structure, such as Cap 0, Cap 1, or Cap 2, is non-negotiable. Our mRNA 5' cap characterization service provides researchers with high-resolution insights into their mRNA constructs. Whether you are using co-transcriptional capping with analogs or post-transcriptional enzymatic capping, we ensure that your capping strategies are optimized for maximal protein expression and minimal immunogenicity.
Key Technologies
- Liquid Chromatography-High Resolution Accurate Mass Spectrometry (LC-HRAM MS)
We utilize state-of-the-art MS to achieve isotopic resolution of 5' fragments. This allows for the precise identification of cap structures and the detection of sub-dalton mass differences caused by methylation or chemical modifications. - DNA Probe-Directed RNase H Cleavage
We employ biotinylated DNA probes complementary to the 5' untranslated region (UTR). Ribonuclease H (RNase H) is then used to selectively cleave a short 5' fragment, which is efficiently isolated and analyzed via MS. - Ion-Pairing Reverse Phase High-Performance Liquid Chromatography (IP-RP-HPLC)
This technique provides superior separation of capped versus uncapped oligonucleotide fragments. By optimizing mobile phase conditions, we achieve baseline separation of species with varying phosphorylation levels and methylation states.
Unlocking Translation Potential through Precision 5' Capping Analysis
As a core component of our mRNA-based vaccine development and therapeutic nucleic acid development platform, CD BioGlyco offers an exhaustive range of analysis services for mRNA structural characterization. Our scope includes:
- Capping Efficiency Quantification
Determining the percentage of mRNA transcripts that successfully incorporate a 5' cap structure relative to uncapped (triphosphate or monophosphate) species. - Cap Structure Identification
Detailed mapping of Cap 0 (m7GpppN), Cap 1 (m7GpppN2'OMe), and Cap 2 structures to ensure biological mimicry and reduced innate immune activation. - Cap Analog Orientation Analysis
For mRNA produced via co-transcriptional capping with analogs like anti-reverse cap analog (ARCA), we verify the orientation of the cap to ensure translational competence. - Impurity and Adduct Profiling
Detection of truncated fragments, failed capping intermediates, and metal adducts that may interfere with downstream therapeutic performance.
Workflow
Sample Receipt and Quality Control (QC)
Upon receiving your mRNA samples, we perform initial assessments of concentration, purity, and integrity using capillary electrophoresis or NanoDrop to ensure the material meets our high analytical standards.
Strategic DNA Probe Hybridization
Based on your mRNA sequence, we design and synthesize high-affinity biotinylated DNA probes that hybridize to a specific site near the 5' end, creating a temporary RNA-DNA duplex target.
Site-Specific Enzymatic Cleavage
RNase H is introduced to the sample. The enzyme recognizes the RNA-DNA hybrid and precisely cleaves the mRNA backbone, liberating the 5' terminal fragment while leaving the remainder of the transcript intact.
Fragment Enrichment and Purification
The 5' fragments are captured using streptavidin-coated magnetic beads. This enrichment step removes the bulk mRNA body and other reaction components, concentrating the target species for high-sensitivity detection.
LC-MS/MS Data Acquisition
The purified 5' fragments are eluted and subjected to IP-RP-HPLC coupled with high-resolution tandem MS. This provides both the accurate mass of the parent ion and diagnostic fragment ions.
Bioinformatic Data Interpretation
Our specialists use advanced software to deconvolve the complex mass spectra, calculate the relative abundance of each cap species, and generate a comprehensive report with quantitative capping efficiency data.
Publication Data
DoI: 10.1261/rna.079173.122
Journal: RNA
IF: 5.0
Published: 2022
Results: This study presents an accessible RNase H-based method for analyzing 5′ cap incorporation, a critical quality attribute of synthetic mRNA. The framework includes designing DNA-RNA chimeras to guide site-specific RNase H cleavage, fluorescently labeling cleavage fragments via Klenow fill-in for gel or capillary electrophoresis readout, and simplifying purification using desthiobiotinylated oligonucleotides and streptavidin magnetic beads with water elution. Thermus thermophilus RNase H achieves more uniform cleavage than E. coli RNase H. The method resolves capping intermediates, requires low RNA input (2.9 µg), and works for modified mRNAs (e.g., pseudouridine-substituted), though pseudouridine alters cleavage specificity. Validated against LC-MS, it offers a cost-effective alternative for mRNA cap analysis, supporting quality control in mRNA vaccine and therapeutic development.
Fig.1 A general scheme of RNase H-based RNA cap analysis. (Chan, et al., 2022)
Applications
mRNA Vaccine Development
Essential for optimizing in vitro transcription (IVT) processes to ensure high protein expression and vaccine potency. Our characterization helps in selecting the most efficient capping enzymes or analogs for large-scale manufacturing.
Gene Replacement Therapy
Used to verify the stability of mRNA therapeutics designed for rare diseases. Accurate capping prevents premature degradation by 5' exonucleases, ensuring a longer therapeutic half-life in target tissues.
Cancer Immunotherapy
Characterization of self-amplifying RNA (saRNA) and conventional mRNA to ensure proper recognition by the host's translational machinery, which is vital for eliciting a robust anti-tumor T-cell response.
Analytical Method Validation
Assessing product purity and providing effective data references for pharmaceutical companies during the process of new drug development.
Advantages
Exceptional Sensitivity and Accuracy
CD BioGlyco utilizes the latest technology to detect low-abundance capping intermediates and impurities that traditional gel electrophoresis cannot resolve, ensuring total transparency of your mRNA's 5' terminal state.
Optimized Fragmentation Strategy
Our DNA probe-directed RNase H cleavage method allows for the analysis of mRNA regardless of its total length, providing high-resolution data for both short transcripts and large, complex saRNA constructs.
Customized Analytical Solutions
We offer tailored probe design and HPLC gradient optimization for challenging mRNA sequences, including those with complex secondary structures that typically hinder standard analytical workflows.
Rapid Project Turnaround
By leveraging a standardized yet flexible workflow and highly automated data processing, we provide comprehensive characterization reports in a timeframe that supports the fast-paced nature of therapeutic development.
Frequently Asked Questions
Customer Review
"We were struggling with inconsistent expression levels in our lead vaccine candidate, and our enzymatic capping step was only 65% efficient. With their insights, we adjusted our protocol and achieved >95% capping."
– F.H., Principal Scientist
"Working with CD BioGlyco saved us months of method development. Their probe-directed cleavage approach worked flawlessly on our large saRNA construct. The report was comprehensive and ready for our requirements."
– A.T., Director of Analytical Chemistry
"The ability to distinguish Cap 0 and Cap 1 abundance in our mRNA samples was exactly what we needed to validate our new co-transcriptional capping strategy."
– D.R., Research Lead
Associated Services
CD BioGlyco provides the advanced analytical tools and biological expertise necessary to ensure your mRNA 5' cap is characterized with unparalleled accuracy. From capping efficiency to complex structural methylation mapping, our services are designed to accelerate your research path. Please feel free to contact us for more information and to discuss your project.
Reference
- Chan, S.H.; et al. RNase H-based analysis of synthetic mRNA 5' cap incorporation. RNA. 2022, 28(8): 1144-1155. (Open Access)